41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer

Natale, R.; Socinski, Mark A.; Hart, L.; Lipatov, Oleg; Spigel, D.; Gershenhorn, Bruce; Weiss, Glen J.; Kazmi, S.M.H.; Karaseva, N.; Gladkov, Oleg; Moiseyenko, V.; Summa, Jason M.

doi:10.1016/s0959-8049(14)70167-4

Cited by 14 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The non-targeted PICN ® is currently in clinical trials in the USA [ 98 ]; Genexol ® , produced by Samyang Biopharm, is a polymeric micelle formulation of paclitaxel that is clinically approved to treat breast cancer in South Korea [ 100 , 101 , 102 ]. BIND-014 ® is composed of a copolymer PLA–PEG and is used for the controlled release of docetaxel against prostate cancer [ 103 , 104 ]. In this particular case, the small-molecule S,S-2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid was used to guide the NPs.…”

Section: Polymeric Nps In Clinical Investigationsmentioning

confidence: 99%

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Niza

Ocaña

Castro‐Osma

et al. 2021

Cancers

View full text Add to dashboard Cite

Many therapeutic agents have failed in their clinical development, due to the toxic effects associated with non-transformed tissues. In this context, nanotechnology has been exploited to overcome such limitations, and also improve navigation across biological barriers. Amongst the many materials used in nanomedicine, with promising properties as therapeutic carriers, the following one stands out: biodegradable and biocompatible polymers. Polymeric nanoparticles are ideal candidates for drug delivery, given the versatility of raw materials and their feasibility in large-scale production. Furthermore, polymeric nanoparticles show great potential for easy surface modifications to optimize pharmacokinetics, including the half-life in circulation and targeted tissue delivery. Herein, we provide an overview of the current applications of polymeric nanoparticles as platforms in the development of novel nanomedicines for cancer treatment. In particular, we will focus on the raw materials that are widely used for polymeric nanoparticle generation, current methods for formulation, mechanism of action, and clinical investigations.

show abstract

Section: Polymeric Nps In Clinical Investigationsmentioning

confidence: 99%

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Niza

Ocaña

Castro‐Osma

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…A Phase II study of BIND-014 in combination with prednisone in patients with metastatic prostate cancer showed an overall response rate of 32% and a median progression-free survival of 9.9 months [ 239 ]. Another Phase II study of BIND-014 as second-line therapy in patients with Stage III/IV non-small cell lung cancer showed a disease control rate of 63% in patients with KRAS mutations [ 240 ]. However, BIND-014 was not effective in later trials against cervical and head-and-neck cancers, leading the company to discontinue its development in 2016 [ 241 ].…”

Section: Clinical Trials On Micellar Drug Delivery Systemsmentioning

confidence: 99%

Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine

Wang

Atluri²,

Tiwari

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Various formulations of polymeric micelles, tiny spherical structures made of polymeric materials, are currently being investigated in preclinical and clinical settings for their potential as nanomedicines. They target specific tissues and prolong circulation in the body, making them promising cancer treatment options. This review focuses on the different types of polymeric materials available to synthesize micelles, as well as the different ways that micelles can be tailored to be responsive to different stimuli. The selection of stimuli-sensitive polymers used in micelle preparation is based on the specific conditions found in the tumor microenvironment. Additionally, clinical trends in using micelles to treat cancer are presented, including what happens to micelles after they are administered. Finally, various cancer drug delivery applications involving micelles are discussed along with their regulatory aspects and future outlooks. As part of this discussion, we will examine current research and development in this field. The challenges and barriers they may have to overcome before they can be widely adopted in clinics will also be discussed.

show abstract

“…Currently, only a short quota of polymeric NPs has been approved by FDA and are clinically used for the treatment of cancer, but many polymeric NPs are being tested in large clinical assays. Of note, paclitaxel encapsulated in a polymeric micelle formulation, Genexol-PM ® , is in clinical trials for several conditions, such as advanced urothelial cancer, metastatic and recurrent breast cancer and gynecological cancer (Kim et al, 2004;Lee et al, 2007;Ribas et al, 2010;Saif et al, 2010;Natale et al, 2014;Zuckerman et al, 2014;Autio et al, 2016;Jain et al, 2016;Von Hoff et al, 2016;Merle et al, 2017). PICN ® , paclitaxelloaded polymeric NPs of polylactide-polyethylene glycol, is being evaluated for metastatic breast cancer (Kim et al, 2004;Saif et al, 2010).…”

Section: Polymeric Nps For the Controlled Release Of Protacsmentioning

confidence: 99%

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

Juan¹,

Noblejas-López

Arenas-Moreira³

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Classical targeting in cancer focuses on the development of chemical structures able to bind to protein pockets with enzymatic activity. Some of these molecules are designed to bind the ATP side of the kinase domain avoiding protein activation and the subsequent oncogenic activity. A further improvement of these agents relies on the generation of non-allosteric inhibitors that once bound are able to limit the kinase function by producing a conformational change at the protein and, therefore, augmenting the antitumoural potency. Unfortunately, not all oncogenic proteins have enzymatic activity and cannot be chemically targeted with these types of molecular entities. Very recently, exploiting the protein degradation pathway through the ubiquitination and subsequent proteasomal degradation of key target proteins has gained momentum. With this approach, non-enzymatic proteins such as Transcription Factors can be degraded. In this regard, we provide an overview of current applications of the PROteolysis TArgeting Chimeras (PROTACs) compounds for the treatment of solid tumours and ways to overcome their limitations for clinical development. Among the different constraints for their development, improvements in bioavailability and safety, due to an optimized delivery, seem to be relevant. In this context, it is anticipated that those targeting pan-essential genes will have a narrow therapeutic index. In this article, we review the advantages and disadvantages of the potential use of drug delivery systems to improve the activity and safety of PROTACs.

show abstract

41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer

Cited by 14 publications

References 0 publications

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

Contact Info

Product

Resources

About